Amphastar Pharmaceuticals (AMPH) Could Be 18% Overvalued After Strong Q3 Earnings And Guidance
Amphastar Pharmaceuticals (AMPH) just paired fresh third quarter results with new fourth quarter guidance, noting high single digit sales growth along with detailed profit figures and a small impairment charge.
Recent trading reflects that story. Amphastar Pharmaceuticals has logged a 10.83% 1 month share price return and a 38.07% 3 month share price return, while the 3 year total shareholder return has declined 48.60%. This leaves longer term holders still underwater despite the rebound.
See how Amphastar Pharmaceuticals compares with other rebounding healthcare stocks by reviewing our hand picked 35 healthcare AI stocks that are already seeing renewed interest.
After Amphastar Pharmaceuticals’ sharp rebound, the real tension is timing. Is this a sensible entry after the jump, or does the math still argue for patience on price?
Most Popular Narrative: 18% Overvalued
On the analyst consensus Narrative on Simply Wall St, Amphastar Pharmaceuticals screens as overvalued, with a fair value of $24.50 against a last close of $28.87. This frames the recent rebound as pricing in a lot of good news already.
The main thing that has to go right is that Amphastar Pharmaceuticals turns heavier spending on capacity, complex generics, and its proprietary pipeline into products that can offset ongoing margin pressure from older drugs and higher operating costs.
The current valuation implies investors are paying a premium for Amphastar Pharmaceuticals despite slowing two year revenue growth and compressed operating margins. This aligns with the view that the stock may be overvalued and exposed if execution disappoints.
See why 30 investors see Amphastar Pharmaceuticals as 18% overvalued.
Result: Fair Value of $24.50 (OVERVALUED)
Still, Amphastar Pharmaceuticals could upset that cautious script if respiratory and glucagon products keep supporting revenue, and if the insulin biosimilar and proprietary pipeline gain meaningful traction.
Find out about the key risks to this Amphastar Pharmaceuticals narrative.
Another View: Amphastar Pharmaceuticals Through Earnings Multiples
Analysts on Simply Wall St see Amphastar Pharmaceuticals as overvalued against a fair value of $24.50. Yet on simple earnings maths, the picture is different. AMPH trades on a P/E of 12.4x, compared with 20x for peers and 14.7x for the wider US Pharmaceuticals industry, and a fair ratio of 13.3x.
That kind of gap can hint at either an opportunity if the market later moves closer to the fair ratio, or a warning that analysts expect weaker progress than the sector. Which interpretation fits your view of Amphastar Pharmaceuticals’ future execution.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages so far on Amphastar Pharmaceuticals, right. If you want to move fast and build your own stance from the data, start with the 2 key rewards and 1 important warning sign
Looking for more Amphastar Pharmaceuticals sized opportunities?
If Amphastar Pharmaceuticals has sharpened your focus, do not stop here. Broader ideas can help you balance risk, find income, and spot fresh upside.
- Target potential mispricing by scanning a curated pool of quality companies that trade below estimated value through the 32 high quality undervalued stocks.
- Build a steadier income stream by searching for robust payers using the 6 dividend fortresses.
- Reduce portfolio stress by concentrating on financially resilient businesses with the 29 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com